Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06370065 | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 17, 2024 |
| clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06365034 | Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma | unknown | — | 92 | Qianfoshan HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06061445 | Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma | unknown | N/A | 22 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06362070 | Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy | unknown | N/A | 75 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06364007 | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | unknown | Phase 2 | 20 | Sulai LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06355700 | Hepatocellular Carcinoma Liver Organoids(HELIO) | unknown | N/A | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06182306 | Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)(PEAR-MET) | unknown | — | 30 | Ourotech, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06342323 | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy(ONFM-SBRT) | unknown | — | 57 | Peking University Third HospitalOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05626985 | Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma | unknown | — | 2,000 | Singlera Genomics Inc.INDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06325267 | Clinical Characteristics of Primary Liver Cancer | unknown | — | 1,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06328283 | The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06156020 | Outcome Analysis of Endoscopic Resection of Pituitary Adenomas | unknown | N/A | 500 | National Cheng-Kung University HospitalOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06322745 | Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy | unknown | N/A | 30 | Al-Azhar UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06317298 | Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy | unknown | N/A | 36 | Peking University First HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04354324 | Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma | unknown | N/A | 254 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302881 | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | unknown | — | 207 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04605185 | Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05870332 | Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy(NAIAD) | unknown | — | 4,000 | King's College Hospital NHS TrustOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05637788 | Artificial Intelligence and Hepatocellular Carcinoma(ARTIHCC) | unknown | — | 535 | Humanitas Clinical and Research CenterOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06229405 | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data | unknown | — | 8,200 | Seoul National University HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06285019 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03781648 | Water Exchange With Narrow Band Imaging on Adenoma Detection(NBI;ADR;WE) | unknown | N/A | 360 | Yuqi HeOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT05591053 | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | unknown | N/A | 70 | Activ SurgicalINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06210334 | HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)(HAI-TL) | unknown | Phase 2 | 54 | Li Xiao WeiOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06148155 | A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06258434 | Liquid Biopsy Based Multiomics Study for Colorectal Cancer Early Screening(COLO-LIMULOID) | unknown | — | 1,000 | Sir Run Run Shaw HospitalOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05028933 | IMC001 for Clinical Research on Advanced Digestive System Malignancies | unknown | Phase 1 | 48 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05173298 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab(HCC) | unknown | — | 100 | CHA UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06247293 | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy | unknown | — | 100 | Zhujiang HospitalOTHER | 0 | Feb 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials